MedPath

Study to evaluate the Efficacy and Safety of a topical Unani Formulation in the Management of Eczema

Phase 2
Conditions
Health Condition 1: L209- Atopic dermatitis, unspecified
Registration Number
CTRI/2023/03/050218
Lead Sponsor
ational Research Institute of Unani Medicine For Skin Disorders
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Participants having the following signs and symptoms of disease: Itching, History of Asthma / hay fever in 1st degree relatives, Visible flexural eczema, Excoriation, Burning sensation, Lichenification, Crusting, Dry skin.

2. Participants who are able and willing to comply with the protocol and to sign ICF

3. Chronicity of more than 6 months and less than 2 years

Exclusion Criteria

1.Participants aged Less than 18 years and more than 65 years

2. Known cases of significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction, Malignancy, HIV infection, AIDS, etc.

3. Any other clinical condition that in the opinion of the investigator would compromise the patientâ??s safety or successful participation in the trial.

4. Pregnancy and Lactation

5. Known allergy, sensitivity or intolerance to the study drug or any of its ingredients

6. Participants with active alcohol intake and/or drug abuse

7. Participants not willing to sign the ICF and to attend treatment schedule regularly.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath